NCT00833417View on ClinicalTrials.gov

A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

November 30, 2010

Study Completion Date

April 30, 2014

Conditions
Basal Cell Carcinoma
Interventions
DRUG

Vismodegib 150 mg

Vismodegib 150 mg was provided in hard gelatin capsules.

Trial Locations (35)

1000

Brussels

2217

Kogarah, New South Wales

2610

Wilrijk

3002

Melbourne

4102

Woolloongabba

10029

New York

19104

Philadelphia

24105

Kiel

32174

Ormond Beach

37203

Nashville

43210

Columbus

44093

Nantes

45122

Essen

51101

Sioux City

55905

Rochester

59037

Lille

60611

Chicago

69495

Pierre-Bénite

72076

Tübingen

75010

Paris

80045

Aurora

85259

Scottsdale

89103

Las Vegas

90025

Los Angeles

94115

San Francisco

94305

Stanford

97080

Würzburg

21231-1000

Baltimore

02114

Boston

02215

Boston

03756

Lebanon

27599-7305

Chapel Hill

77030-4095

Houston

SW3 6JJ

London

BH15 2JB

Poole

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY